Resistance map
Where resistance comes from in the hospital's catchment, and how the hospital compares with Europe. The regional view uses the patients' home areas in the laboratory extract; the European view uses national EARS-Net figures published by ECDC.
Catchment areas · % of Escherichia coli resistant to ceftriaxone
2023-12-24 → 2024-12-22 · first isolatesSynthetic areas: the extract only gives five abstract home areas around Tyks (Turku). The layout below is schematic, not real municipal borders.
Compare this organism across wards in the resistance view →| Area | First isolates | Tested | Value | 95 % CI |
|---|---|---|---|---|
| North | 874 | 874 | 3.0 % | 2–4 % |
| West | 320 | 320 | 3.4 % | 2–6 % |
| Centre | 380 | 380 | 2.6 % | 1–5 % |
| East | 388 | 388 | 5.9 % | 4–9 % |
| South | 874 | 874 | 3.3 % | 2–5 % |
Europe · E. coli resistant to 3rd-generation cephalosporins
EARS-Net 2024 · invasive isolates% of invasive E. coli isolates (blood, CSF) resistant to cefotaxime, ceftriaxone or ceftazidime.
Dataset: ceftriaxone-resistant E. coli from blood cultures (EARS-Net counts any of cefotaxime, ceftriaxone or ceftazidime). The extract is synthetic: the comparison shows the method, not Tyks' real level.
Source: ECDC EARS-Net, Antimicrobial resistance - Annual Epidemiological Report - Country summaries - 2024 data (published 2025-11-18), via ECDC EARS-Net. Values are shipped in data/ears-net.csv. Liechtenstein reported too few
isolates.